問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



CHANGHUA CHRISTIAN HOSPITAL

  • 0

    Total Beds

  • 0

    Total Doctors

  • 500Changhua CountyChanghua Changhua

Recruiting Trial

278Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

789Cases

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    錠劑 膜衣錠

Participate Sites
12Sites

Not yet recruiting1Sites

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    錠劑 膜衣錠

Participate Sites
10Sites

Not yet recruiting1Sites

2024-11-01 - 2027-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2024-11-01 - 2029-08-31

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2024-11-27 - 2028-05-29

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting
Multicenter, Phase III, Randomized, Placebo-controlled, Double-blind Study of Combination Therapy with D07001 Softgel Capsules and Capecitabine Versus Placebo and Capecitabine in Participants with Advanced Biliary Tract Cancer after Treatment Failure with Gemcitabine, Platinum, and FOLFOX or Irinotecan Regimens

  • Condition/Disease

    Biliary Tract Cancer (BTC)

  • Test Drug

    CAPECITABINE D07001-Softgel Capsules Placebo 艾結達膜衣錠 500 毫克 克癌特膜衣錠150毫克 克癌特膜衣錠500毫克 截瘤達錠５００毫克

Participate Sites
9Sites

Not yet recruiting9Sites

2025-02-28 - 2032-06-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2025-03-01 - 2029-12-31

Others

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-03-07 - 2032-02-28

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2025-03-31 - 2028-01-31

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

1 8 9 10 11 12 79
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB